Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Finasteride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 known ✓ | P31213 | 9/20 | 1.00 |
| ▸ | SRD5A1 | P18405 | 16/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | HSD3B1 | P14060 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Finasteride SCHEMBL1560981 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL5148287 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL5509 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL13575812 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL21969512 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL3982016 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL22032590 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL22564355 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL21969513 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| Finasteride SCHEMBL6448111 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190282591-A1 | FINASTERIDE AND SILDENAFIL COMPOSITIONS AND APPLICATIONS | BLUE GOOSE DRUGS INC (CA) | 2019-09-19 | — | — | US | claimed |
| US-20140142124-A1 | Compositions for Topical Application Having Androgenic Actions | AVENTIS PHARMA SA (DE) | 2014-05-22 | — | — | US | claimed |
| US-7998970-B2 | Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders | PROTEOSYS AG (DE) | 2011-08-16 | — | — | US | claimed |
| US-7872135-B2 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2011-01-18 | — | — | US | claimed |
| EP-1523490-B1 | METHOD FOR INTRODUCING A 1,2 DOUBLE BOND INTO 3-OXO-4-AZASTEROID COMPOUNDS | SIEGFRIED GENERICS INT AG (CH) | 2009-12-23 | — | — | EP | claimed |
| US-20090170889-A1 | USE OF FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICALLY-ASSOCIATED DISORDERS | PROTEOSYS AG (DE) | 2009-07-02 | — | — | US | claimed |
| EP-2065038-A1 | New therapeutic approaches for treating Charcot-Marie-Tooth disease | Pharnext (FR) | 2009-06-03 | — | — | EP | claimed |
| EP-0599376-B2 | A process for the production of finasteride | MERCK & CO INC (US) | 2008-04-16 | — | — | EP | claimed |
| EP-1824495-A2 | FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR PREVENTING/TREATING NEUROLOGICALLY-ASSOCIATED DISORDERS | ProteoSys AG (DE) | 2007-08-29 | — | — | EP | claimed |
| EP-1790653-A2 | Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it | Dr. Reddy's Laboratories Ltd. (IN) | 2007-05-30 | — | — | EP | claimed |
| EP-0542802-A1 | STIMULATION OF HAIR GROWTH WITH POTASSIUM CHANNEL OPENERS AND 5-g(a)-REDUCTASE INHIBITORS. | UPJOHN CO (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0536843-A1 | Antiandrogen-5-alpha-reductase inhibitor compositions and their preparation | STERLING WINTHROP INC. (US) | 1993-04-14 | — | — | EP | claimed |
| US-5175155-A | Antiandrogen for treating prostate disease in male mammals | STERLING WINTHROP INC. (US) | 1992-12-29 | — | — | US | claimed |
| WO-1992002225-A1 | STIMULATION OF HAIR GROWTH WITH POTASSIUM CHANNEL OPENERS AND 5α-REDUCTASE INHIBITORS | THE UPJOHN COMPANY (US) | 1992-02-20 | — | — | WO | claimed |
| EP-0155096-B1 | 17 BETA-SUBSTITUTED-4-AZA-5-ALPHA-ANDROSTENONES AND THEIR USE AS 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1989-10-04 | — | — | EP | claimed |
| EP-0298652-A2 | Dehydrogenation process and intermediates | MERCK & CO. INC. (US) | 1989-01-11 | — | — | EP | claimed |
| EP-0285383-A2 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | claimed |
| EP-0285382-A2 | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | claimed |
| US-4760071-A | Enzyme inhibitor | MERCK & CO., INC. (US) | 1988-07-26 | — | — | US | claimed |
| EP-0155096-A2 | 17 Beta-Substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1985-09-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170889-A1 | USE OF FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICALLY-ASSOCIATED DISORDERS | SLC25A4, CHRNA10, SLC25A20 | SRD5A2 708/4885SRD5A1 511/4885LMNA 2435/4885 |
| US-20140142124-A1 | Compositions for Topical Application Having Androgenic Actions | NR5A1, CYP17A1, CYP19A1 | SRD5A2 11/4885SRD5A1 7/4885LMNA 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.